Luminary’s novel CAR design replaces the traditional scFv with the natural B-cell Activation Factor Ligand (BAFF-L). BAFF-L naturally binds to three receptors found on B cells: BAFF-R, BCMA, & TACI. At least one of these three receptors is expressed on all B-cell lineages.

BAFF-L CAR has several benefits over traditional scFv-based CARs:

1. Mitigates antigen escape by targeting multiple antigens on each pathogenic B cell simultaneously
2. Targets long-lived plasma cells missed by CD19-targeted CARs
3. Targets multiple B cell derived cancers and autoimmune indications using the same CAR-T cell product
4. Triple antigen targeting expands the breadth of applicable B cell cancers amenable to the therapy.

Luminary’s BEACON technology is a ground-breaking innovation design to combat advanced solid tumor cancers by using γδ CAR-T cells with potent antigen presentation cell (APC) capabilities.

BEACON cells combine CAR targeting with APC presentation of cancer antigens in a singular cellular chassis.

1. Direct tumor killing through classical CAR mechanisms
2. Proprietary induction of durable γδ T cell APC function
3. Engineered to present dozens of tumor associated antigens (TAAs) and recurrent neoantigens on MHCI and MHC II
4. APC function activates endogenous αβ T to induce secondary immune responses leading to long-term, durable responses

Luminary’s innovative split CAR technology optimizes co-stimulation for dual-targeting CARs without inducing exhaustion.

Our novel design delivers multiple benefits:

1. Targets two antigens to avoid antigen escape
2. Modular logic-gate design for full activation
3. Rapid and sustained anti-tumor effects
4. Increased cellular metabolic fitness
5. Adaptable design for any CAR binding domain